FluoroPharma’s Bet On Next-Gen Molecular Imaging Agents
This article was originally published in The Pink Sheet Daily
Executive Summary
Molecular imaging’s technological advances are impressive, but getting the business model right and investors on board has been hard for start ups in the field. FluoroPharma CEO Thijs Spoor believes his company, which has several cardiovascular imaging agents in clinical trials, is on the right track and ripe for partnerships.